PreprintArticleVersion 2Preserved in Portico This version is not peer-reviewed
Inactivated tilapia lake virus vaccine formulated with MontanideTM ISA 763A VG adjuvant resulted in inadequate protection and poor immunity in vaccinated Nile tilapia
Version 1
: Received: 19 June 2023 / Approved: 21 June 2023 / Online: 21 June 2023 (05:50:45 CEST)
Version 2
: Received: 7 July 2023 / Approved: 10 July 2023 / Online: 10 July 2023 (05:03:59 CEST)
How to cite:
Mai, T.T.; Thompson, K.D.; Senapin, S.; Rodkhum, C.; Dong, H.T. Inactivated tilapia lake virus vaccine formulated with MontanideTM ISA 763A VG adjuvant resulted in inadequate protection and poor immunity in vaccinated Nile tilapia. Preprints2023, 2023061486. https://doi.org/10.20944/preprints202306.1486.v2
Mai, T.T.; Thompson, K.D.; Senapin, S.; Rodkhum, C.; Dong, H.T. Inactivated tilapia lake virus vaccine formulated with MontanideTM ISA 763A VG adjuvant resulted in inadequate protection and poor immunity in vaccinated Nile tilapia. Preprints 2023, 2023061486. https://doi.org/10.20944/preprints202306.1486.v2
Mai, T.T.; Thompson, K.D.; Senapin, S.; Rodkhum, C.; Dong, H.T. Inactivated tilapia lake virus vaccine formulated with MontanideTM ISA 763A VG adjuvant resulted in inadequate protection and poor immunity in vaccinated Nile tilapia. Preprints2023, 2023061486. https://doi.org/10.20944/preprints202306.1486.v2
APA Style
Mai, T.T., Thompson, K.D., Senapin, S., Rodkhum, C., & Dong, H.T. (2023). Inactivated tilapia lake virus vaccine formulated with MontanideTM ISA 763A VG adjuvant resulted in inadequate protection and poor immunity in vaccinated Nile tilapia. Preprints. https://doi.org/10.20944/preprints202306.1486.v2
Chicago/Turabian Style
Mai, T.T., Channarong Rodkhum and Ha Thanh Dong. 2023 "Inactivated tilapia lake virus vaccine formulated with MontanideTM ISA 763A VG adjuvant resulted in inadequate protection and poor immunity in vaccinated Nile tilapia" Preprints. https://doi.org/10.20944/preprints202306.1486.v2
Abstract
Tilapia tilapinevirus, or tilapia lake virus (TiLV), is a virus that has caused disease outbreaks in many countries worldwide since 2009. We recently developed two simple but effective TiLV vaccines based on heat-killed virus (HKV) and formalin-killed virus (FKV). In the present study, we evaluated the immunological response and efficacy of MontanideTM ISA 763A VG oil-based vaccines (O-HKV and O-FKV) in Nile tilapia (Oreochromis niloticus) and compared these responses in fish vaccinated with water-based formulations (W-HKV and W-FKV). Juvenile Nile tilapia were given primary and booster vaccinations with the vaccine formulations. The relative fold change in expression of five immunoglobulin genes (IgM, IgT, IgD, CD4 and CD8) was assessed before and after booster vaccination, and a challenge with TiLV was performed to evaluate the efficacy of the vaccines. The results showed that the water-based vaccines induced higher levels of Ig transcripts and conferred significantly higher levels of protection compared to the oil-based formulations, with relative percent survival (RPS) values ranging from 54.6% to 59.7% for W-HKV and W-FKV vaccinated fish, and 32% and 0% for the O-HKV and O-FKV vaccinated fish, respectively. These findings suggest that water-based vaccines are more effective at protecting tilapia against TiLV infection, and MontanideTM ISA 763A VG may not be a suitable adjuvant for formulating whole-inactivated TiLV vaccines.
Keywords
tilapia lake virus; TiLV; Nile tilapia; vaccine; adjuvants; MontanideTM ISA 763A VG
Subject
Biology and Life Sciences, Aquatic Science
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
